Resistance alterations were evident in the recurrent tumor: high-level PDGFRA amplification (111 copies) and an in-frame MDM2::PDGFRA fusion – exon 1 of MDM2 (NM_001145339.2, breakpoint 15 bp into exon 1) joined in-frame to exon 8 of PDGFRA (NM_006206.6) (Fig. 2C, D). The gene discussed is PDGFRA; the disease is neoplasm.